Join us for the 5th Annual Symposium on Hidradenitis Suppurativa Advances – online! Due to the ongoing restrictions of Covid19, the 5th SHSA will be held virtually, to allow for maximum participation and to provide learning opportunities for physicians, AHW. medical students and a patients.
Symposium on Hidradenitis Suppurativa Advances (SHSA) provides an interdisciplinary forum for leading academic scientists, clinicians and researchers to share their experiences, discuss innovations and research regarding Hidradenitis Suppurativa (HS). Patients and caregivers are encouraged to learn from the science presented. Support chat groups are planned for this virtual format.
The 5th SHSA will include interactive educational sessions, including two live 110-120 minute sessions each day on October 10 and 11. Included in this online format:
|
Iltefat Hamzavi, MD, FAAD
President, HSF
|
|
|
|
 |
| Call for Abstracts opens | February 2020 |
| Online registration opens | February 2020 |
| Abstract submission deadline | July 3, 2020 |
| Notice of Abstract adjudication | July 24, 2020 |
| 2nd Call for Abstracts/Late-breaking opens | Monday July 27, 2020 |
| 2nd Call for Abstracts deadline | August 14, 2020 |
| Deadline for presenting authors to register | August 28, 2020 |
| Online registration closes | September 30, 2020 |
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Dermatology Association.
You may claim a maximum of 7.5 hours (credits are automatically calculated).
AMA (Agreement dates: January 1, 2017 to December 31, 2020)
Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Visit the AMA website for more information on the process to convert Royal College MOC credit to AMA credit.
EUMS (Agreement dates: December 20, 2016 to December 31, 2020)
Live educational activities recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medical Specialists (UEMS) eligible for ECMEC®.
QCHP (Agreement dates: January 1, 2017 to December 31, 2021)
Through an agreement between the Royal College of Physicians and Surgeons of Canada and the Qatar Council for Healthcare Practitioners, healthcare practitioners participating in the QCHP CME/CPD program may record MOC Section 1 or MOC Section 3 credits as QCHP Category 1 or Category 3 credits.
PROGRAM
Log on to the virtual conference platform. All registered attendees will receive a unique link and log in one week prior to the conference.
Create your personal profile. View on-demand presentations, abstracts and poster presentations. Visit the virtual Exhibit Hall.
Patients and Caregivers are welcome to join Moderators Dr. Michelle Lowes and Dr. Joslyn Kirby for this Welcome to the 5th SHSA.
All HCPs are welcome to join this informal chat room, moderated by Dr. Michelle Lowes and Dr. Haley Naik.
All attendees are invited to join this sponsored satellite symposium.
This is an informal discussion, moderated by Sandra Guilbault, Hope for HS
Session is open to all new and experienced HCPs with an interest in mentorship. This is an informal discussion, moderated by Dr. Steven Daveluy and Dr. Stephanie Goldberg
9:00 am - 5:00 pm ET
Sponsor Exhibit Profiles
Visit at your leisure on the conference virtual platform
Scheduled times to meet with the exhibitor reps are listed in the schedule below.
Patients and Caregivers are invited to join this informal session, moderated by Dr. Raed Alhusayen and Dr. Isabelle Delorme.
Session Learning Objectives:
1. To describe recent data related to the epidemiology and burden of HS
2. To discuss HS Covid registry findings
3. To review research funding opportunities for HS
See individual abstracts in the Final Program and Abstract Book for individual presentation learning objectives (avail for download above).
Moderator: Dr. Joslyn Kirby
Times are in Eastern Time
10:00 am: NIAMS Update, Ricardo Cibotti, Bethesda, MD, USA
10:10 am: Making the most of visits with HS patients, Christopher Sayed, Chapel Hill, NC, USA
10:30 am: COVID19 Registry Discussion, Haley Naik, San Francisco, CA, USA
10:50 am: Provider perspectives and practice patterns on the management of hidradenitis suppurativa in pregnancy, Jennifer Hsiao, Los Angeles, CA, USA
10:58 am: Comorbidity screening in HS: evidence-based recommendations from the US and Canadian HSFs, Amit Garg, New Hyde Park, NY, USA
11:06 am: Outcomes of Pregnancy, Childbirth, and Pueperium, Surav M. Skaya
11:14 am: Pregnancy in HS: Patient perspectives and practice gaps, Natalie M. Villa, Los Angeles, CA, USA
11:22 am: Pain severity and management of HS at Emergency Department Visits in the US, Matthew T. Taylor, Philadelphia, PA, USA
11:30 am: Panel Q&A: All presenters will be live for Q&A
Patients and Caregivers are invited to join this informal session, moderated by Dr. Simon Wong, Dr. Afaneh Alavi and Dr. Vivian Shi
Session Learning Objectives:
1. To describe recent data related to the bench research pertaining to HS
2. To discuss cutting edge translational research findings for HS9
3. To review the perturbations in the microbiome associated with HS
See individual abstracts in the Final Program and Abstract Book for individual presentation learning objectives (avail for download above).
Moderator: Dr. Simon Wong
Times are in Eastern Time
12:30 pm: Microbiome Research, Amanda Nelson, Hershey, PA, USA
12:50 pm: Translational Research – From biobank to bench: Understanding immune dysregulation in hidradenitis suppurativa, Angel Byrd, Washington, DC, USA
1:10 pm: Drug repurposing for hidradenitis suppurativa treatment, Christos Zouboulis, Dessau, Germany
1:18 pm: Immunopathogenesis of HS and Response to Therapy, Margaret M. Lowe, San Francisco, CA, USA
1:26 pm: Localization of Upregulated Proteins in Hidradenitis Suppurativa, Courtney A. Prestwood, Dallas, TX, USA
1:34 pm: Expression of antimicrobial peptides in lesional keratinocytes of patients with HS, Thomas Meyer, Bochum, Germany
1:42 pm: Panel Q&A: All presenters will be live for Q&A
Interested in incorporating the latest real-world evidence in hidradenitis suppurativa management into your practice? Then mark your calendar to attend New approaches based on the latest evidence in HS management presented virtually at the 5th annual Symposium on Hidradenitis Suppurativa Advances (SHSA), October 10, 2020 at 3 pm (EDT). This case-based program will take you through the perioperative use of biologics to optimize surgical outcomes, integrating collaborative care models and contextualizing real world evidence for real world practices. Developed and presented experts in hidradenitis suppurativa, Dr. Irina Turchin and Dr. Ralph George, this presentation offers expert opinion to help you evaluate and incorporate the most recent real-world evidence into your HS practice.
Learning Objectives:
• Evaluate recent RWE in HS treatment decision-making to maximize patient outcomes
• Assess the latest data on the perioperative use of biologics for optimal surgical outcomes
• Consider the value of a collaborative approach in HS management
Presenters:
Irina Turchin, MD, FRCPC, Assistant Professor, Division of Clinical Dermatology & Cutaneous Science, Department of Medicine, Dalhousie University
Dermatology Consultant, Horizon Health Network Fredericton, NB
Investigator, Probity Medical Research, Waterloo, ON
Ralph George, MD, FRCS
Associate Professor of General Surgery at the University of Toronto
Medical Director of the CIBC Breast Centre at St. Michael's Hospital
President of the St. Michael's Hospital Medical Staff Association
Executive Board Member of the Canadian Breast Cancer Foundation
Co-chair for the Hidradenitis Suppurativa Advisory Board of Canada, Toronto, ON
Sponsor reps are available by video call within the exhibit profiles at the scheduled times noted below.
HCPs are invited to join this informal chat session on Surgery, moderated by Dr. Stephanie Goldberg and Dr. Ralph George.
All patients and caregivers are invited to this informal session, moderated by Dr. Elizabeth O'Brien, Dr. Afsaneh Alavi and Dr. Iltefat Hamzavi.
Session Learning Objectives:
1. To review the treatment of HS, including multimodality treatment
2. To discuss research related to HS phenotypes
3. To describe recent data related to the novel HS therapeutics
See individual abstracts in the Final Program and Abstract Book for individual presentation learning objectives (avail for download above).
Moderator: Dr. Isabelle Delorme
Times are in Eastern Time
10:00 am: Treatment Combinations, Mark Kirchhof, Ottawa, ON, Canada
10:20 am: HS Clinical Phenotypes, Hessel van der Zee, Rotterdam, The Netherlands
10:40 am: Antibiotherapy targeted against hidradenitis suppurativa flora may significantly improve inflammatory bowel disease symptoms, Aude Nassif, Paris, France
10:48 am: Prevalence and Risk Factors for Anemia in a Population with Hidradenitis Suppurativa, Sydney R. Resnik, Miami, FL, USA
10:56 am: A Randomized, Placebo-Controlled, Phase 2 Study of the Janus Kinase 1 Inhibitor INCB054707 for Patients With Moderate-to-Severe Hidradenitis Suppurativa, Afsaneh Alavi, Toronto, ON, Canada
11:04 am: A Patient Survey of Pain Management Modalities used in Hidradenitis Suppurativa, Jennifer M. Fernandez, Tucson, AZ, USA
11:12 am: Diet, supplementation, and topical home remedies in HS: is there an adjunctive role?, Annika S. Silfvast-Kaiser, Dallas, TX, USA
11:20 am: The Use of Brodalumab in Hidradenitis Suppurativa: Results from Two Open Label Cohort Studies, John Frew, New York, NY, USA
11:28 am: Panel Q&A: All presenters will be live for Q&A
This is an informal discussion on the Treatment of HS Procedures, moderated by Dr. Ralph George and Dr. Elizabeth O'Brien.
Session Learning Objectives:
1. To discuss research findings for novel HS outcome measures
2. To describe research pertaining to HS disease states and measurement
3. To review aspects of clinical trial design for HS
See individual abstracts in the Final Program and Abstract Book for individual presentation learning objectives (avail for download above).
Moderator: Dr. Stephanie Goldberg
Times are in Eastern Time
12:30 pm: The HS-patient decision aid: practical aspects and future directions, Jerry Tan, Windsor, ON, Canada
12:50 pm: The Outcome Measure May Vary By the Drug Mechanism of Action and Immune Mediated Inflammatory Disease Being Treated, Wayne Gulliver, St. John's, NL, Canada
1:10 pm: Evaluating the responsiveness and score bands of the HiSQOL, a novel HS-specific patient-reported outcome measure, Joslyn S. Kirby, Hershey, PA, USA
1:18 pm: Novel approach to HS flare measurement using patient-reported outcomes, Joslyn S. Kirby, Hershey, PA, USA
1:26 pm: Quantifying the Natural Variation in Lesion Counts Over Time in Untreated Hidradenitis Suppurativa: Implications for Outcome Measures and Trial Design, John W. Frew, New York, NY, USA
1:34 pm: Do HS trial participants reflect the HS patient population?, Victoria M. Madray
1:42 pm: Development and validation of an Investigator Global Assessment in HS, Amit Garg, New Hyde Park, NY, USA
1:50 pm: Panel Q&A: All presenters will be live for Q&A
Conference closing remarks by
Dr. Joslyn Kirby, Co-Chair
Dr. Isabelle Delorme, Co-Chair and President, CHSF
Dr. Iltefat Hamzavi, President, HSF
HSF Patient Perspective, Sandra Guilbault and CHSF Patient Perspective, Victoria DiNardo
Last chance to speak with a representative. Visit the Sponsor Exhibit Profiles.
All patients and caregivers are invited to this informal discussion, moderated by Dr. Michelle Lowes and Dr. Joslyn Kirby.
SPEAKERS
The SHSA Committee have ensured the program features the most highly-regarded speakers in the field of HS, rising stars and HS researchers. These speakers are leading efforts to treat HS in the best possible way, and spearheading HS research.
Speaker
A Dermatologist experienced as a clinician, educator, administrator, clinical and basic science researcher. Has been in clinical practice for almost thirty years and has supervised over 250 clinical trials covering many aspects of dermatology with the focus in genetics, psoriasis, wound care, virology and hidradenitis suppurativa. He has more than 100 published papers authored or co-authored, as well as over 200 abstracts authored or co-authored. Professor and Chair of the Discipline of Medicine, Memorial University of Newfoundland (2009-2011), as well as Head of Dermatology, Faculty of Medicine, Memorial University of Newfoundland (1989-present). Adjunct Professor, Henan University of Traditional Chinese Medicine, and Zhengzhou University, Henan, PR China. Chair & Medical Director of NewLab Clinical Research Inc. (1996-2009), Chief Scientific Officer, NewLab Life Sciences (2009-2011). Former President of Matrixx Cosmetic Laser Clinic, Vice-President of Focus Continuing Education Inc., Vice-President of the Canadian Dermatology Association (1996-1997) and Chair of the organizing committee for the CDA meeting (1996-1997), St. John’s, Newfoundland. Former Chief, Division of Dermatology, Eastern Health, St. John’s, Newfoundland (1996-2008). Co-founder of Newfound Genomics (a Newfoundland & Labrador based genomics company). Former member of the Governing Council of the National Research Council (2003-2006); CEO of Advanced Immuni T Inc. (Canada) and Advanced Immuni T Inc. (USA) (2003-2005). Member of the Editorial Board for the Journal of Cutaneous Medicine and Surgery and Medical Editor The Chronicle of Skin & Allergy. Reviewer for Clinical and Experimental Dermatology, the BMJ (British Journal of Dermatology UK) and British Journal of Dermatology. Previous member of the College of Reviewers for the Canada Research Chairs Program (2007-2010), Chair, Newfoundland and Labrador Association of Technology Industries (NATI) (2008/09), Chair and Board Member, Newfoundland and Labrador Science Centre.
Speaker
Ricardo Cibotti, Ph.D., Program Director, Immunobiology and Immune Diseases of Skin Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Health, USA
Speaker
Dr. Mark Kirchhof, MD, PhD, FRCPC obtained his Bachelor of Science in Molecular Biology from McMaster University before joining the MD/PhD program at Western University. His PhD research involved studies of the signalling pathways important to immune system regulation. He then went on to complete his dermatology residency at the University of British Columbia. He was the dermatology education director at Queen’s University in Kingston for 3 years, coordinating and leading undergraduate, post-graduate and CME educational activities. He has published over 50 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national and international meetings. He is now the head of the Division of Dermatology in Ottawa.
Speaker
Dr. Jerry Tan trained in internal medicine at the University of Toronto and in dermatology at University of British Columbia and University of Michigan. His general dermatology and aesthetic practices are in Windsor Ontario Canada. Dr. Tan conducts clinical trials research at Windsor Clinical Research, a clinical trials site in dermatology. Topics in dermatology of research interest include acne, rosacea, hidradenitis suppurativa. Additional interests include outcome measurements and informed shared decision making in dermatology. Dr. Tan's group has developed 3 patient decision aids in dermatology – acne, psoriasis and hidradenitis suppurativa. He currently chairs the working group on clinical practice guidelines of the Canadian Dermatology Association, and co-chairs the rosacea international consensus group (ROSCO) and the acne core outcomes research network (ACORN). He has authored or co-authored more than 100 peer-reviewed publications.
Speaker
In 2011, Hessel defended his PhD thesis: Hidradenitis suppurativa (HS); Pathogenesis and treatment of hidradenitis suppurativa (HS) at the Erasmus University of Rotterdam (Netherlands). His thesis contained fundamental laboratory research as well as clinical studies. Hereafter, during his training as a dermatologist, he remained active in the field of HS research supervising several PhD students. Since 2016 he works as a dermatologist at the department of dermatology Erasmus MC and DermaHaven in Rotterdam. He set up specialized HS consulting hours integrated research to improve patient care. In his research he has close collaborations with many international HS experts. Furthermore, he is a pro bono medical advisor for the Dutch HS patient foundation and founding member of the European HS foundation as well as the Dutch HS expert group. He participated in national and international HS guidelines. Till 2020, he has published over 70 peer-reviewed international papers.
Speaker
Haley Naik is Assistant Professor of Dermatology and Director of the Hidradenitis Suppurativa Clinic and Research Program at the University of California, San Francisco.
She completed medical school and dermatology residency at Harvard Medical School, and went on to complete a postdoctoral clinical research fellowship at the National Institutes of Health and received a Masters of Health Sciences from Duke University.
She established the UCSF Hidradenitis Suppurativa Clinic and Research Program in 2016, and the multi-center Hidradenitis Suppurativa PRospective Observational REgistry and bioSpecimen repoSitory (HS PROGRESS) in 2018. The primary goals of her research are to uncover the mechanisms underlying HS in order to identify novel therapeutic targets, and to better understand the impact of HS on the lives of people who live with this devastating disease.
In her free time, she enjoys puzzles, the beach, and traveling with her husband and 2 delightful daughters.
Speaker
Dr. Sayed is an Associate Professor of Dermatology at the University of North Carolina at Chapel Hill where he also completed his undergraduate, medical school, and residency training. He is Director of the Hidradenitis Suppurativa Clinic at UNC where he focuses on a multidisciplinary approach including medical, laser, and surgical management of HS. He is a directing member of the HS Foundation, serves as medical lead the local chapter of the Hope for HS support group, and co-chaired development of the first North American Clinical Management Guidelines for HS. Current research efforts include roles as an investigator in clinical trials and basic science research exploring the underlying genetic mechanisms of HS.
Speaker
Angel S. Byrd, M.D., Ph.D.
Assistant Professor | Adjunct Assistant Professor
Departments of Dermatology
Howard University College of Medicine | Johns Hopkins University School of Medicine
Angel was born and raised in Edwards and Jackson, Mississippi. She obtained her BS (’04) from Tougaloo College in Tougaloo, Mississippi and MD (’16), PhD (’14) from Warren Alpert Medical School of Brown University in Providence, Rhode Island. She completed an Ethnic Skin Postdoctoral Fellowship at Johns Hopkins University School of Medicine (JHUSOM) under the direction of Dr. Ginette Okoye. Currently, she is an Assistant Professor at Howard University College of Medicine and Adjunct Assistant Professor at JHUSOM (Departments of Dermatology) where her work centers on the establishment of tissue biobanks to understand the immunopathological mechanisms contributing to ethnic skin diseases, particularly among African-American patients with Hidradenitis suppurativa. Her main research focus is elucidating the unreported roles of neutrophils and the innate immunity in the induction of local and systemic immune dysregulation. Angel leads multidisciplinary collaborative projects with the overarching goal of establishing a scientifically-driven approach to treatment options for patients suffering from these debilitating diseases. She has contributed to the scientific literature, given numerous lectures, national/international talks, and has been featured on the BET 33rd Annual UNCF An Evening of Stars® international program, recognizing her as one who is “changing the face of science, one mind at a time.”
Speaker
Assistant Professor of Dermatology
Pennsylvania State University College of Medicine
Amanda Nelson, PhD, is an Assistant Professor of Dermatology at the Pennsylvania State University College of Medicine in Hershey, PA. Dr. Nelson received her graduate degree in Molecular Medicine at the Pennsylvania State University College of Medicine where she studied the mechanism of action of isotretinoin in the treatment of acne vulgaris. Dr. Nelson completed two postdoctoral research fellowships in dermatology at Penn State and at Johns Hopkins University where she expanded her expertise in sebaceous glands, hair follicles, skin stem cells and wound healing. Her research interests lie in understanding the pathomechanisms of inflammatory skin diseases (acne, hidradenitis suppurativa) and the impact of the skin microbiome in inflammatory skin disease. Her work is supported by grants from NIH/NIAMS, American Acne and Rosacea Society, Hidradenitis Suppurativa Foundation and the Acne Cure Alliance. Dr. Nelson serves as a reviewer for multiple journals including the Journal of Investigative Dermatology. Dr. Nelson has authored numerous manuscripts and book chapters on sebaceous glands, hair follicles and wound-healing and currently holds multiple patents related to her work.
All registered attendees were emailed a link from the SHSA App that will enable you to log onto the conference platform. We recommend you bookmark this link for easy access to the SHSA App. Go to: https://5th-annual-symposium.pathable.co/
Physician, Nurse/Allied Health, Resident/Fellow, Medical Students and Patients/Caregivers have full access to all virtual SHSA activities, including:
Registration fees are in $ CAD; Ontario taxes (13% HST) will be applicable to registration fees shown below. Online registration is now open.
| CONFERENCE | Cost |
|---|---|
| Physician (Dermatologist or other specialist) |
$200
|
|
Nurse or Allied Health Worker*
|
$200 |
| Resident* or Fellow* |
$100
|
|
Medical Student*
|
$75
|
|
Patient / Caregiver**
|
$50
|
|
Industry Sponsor***
|
$300
|
|
Non-sponsoring Industry
|
$1000 |
Online registration will close at midnight PST on Wednesday, September 30, 2020. Login instructions for the virtual conference platforms will be sent to all registered attendees by email one week prior to the conference.
*If you are a Resident, Fellow, Nurse, Allied Worker or Medical Student in training, your registration can only be confirmed upon receipt of written verification of your status by the chairman of your department or program director. Residents, Fellows and Medical Students must be in full-time enrollment in the current academic year. Please upload your verification letter/status when registering online.
**Patient/caregiver: limited number of registrants permitted on first-registered basis. See below for further information in Registration Terms.
***Industry Sponsors – a number of complimentary registrations are provided to sponsors, depending on sponsor level. A discount code will be provided to the main sponsor contact for distribution to the sponsor reps.
Payment can be made online by Credit Card (Visa or MasterCard) via the Conference Secretariat’s secure merchant account. If you are unable to register online, request a Registration Form from the Conference Secretariat at shsa@simplyeventful.com.
All registrants to the 5th SHSA must read and agree to the Registration Terms & Cancellation Policy in order to confirm your registration.
REGISTRATION TERMS FOR PATIENT / CAREGIVER CATEGORY
As the SHSA is intended to educate medical and scientific professionals who treat HS patients and have advanced medical knowledge, patients/caregivers agree that the information presented may be disturbing and will be presented at a high level of learning.
In order to confirm registration in this category, Patients / Caregivers must agree to the following terms:
Registration fees will be refunded upon written request to the Conference Secretariat by the following terms:
Submit cancellation letters to the Conference Secretariat by e-mail (shsa@simplyeventful.com) or fax (604-738-8697).
The Canadian Hidradenitis Suppurativa Foundation (CHSF) and its appointed suppliers act as agents for, and make arrangements with companies providing services. Although great care is taken to choose suppliers, we are unable to control them directly and, therefore, cannot be responsible for their acts or omissions. A failure to supply the activity or service or a deficiency in same or damages which may arise during such activity are not the responsibility of the CHSF and its appointed suppliers and the submission of a registration form is based on this limitation. The CHSF, its employees, officers, volunteers, directors, contracted staff, contracted companies and agents cannot assume responsibility for any claims, losses, damages, costs or expense arising out of injury, accident or death, loss or damage to property, delay or inconvenience arising from any matters referred to herein.
A second Call for Abstracts for new and late-breaking submissions was opened at the end of July. Deadline for the 2nd Call for Abstracts was August 14, 2020. Thank you for your submissions.
|
View the instructions below or download the PDF. Submissions will only be accepted online.
|
|
Call for Abstracts and online registration opens
|
February 2020
|
|
Abstract submission deadline
|
July 3, 2020
|
|
Notice of Abstract adjudication
|
July 24, 2020
|
|
2nd Call for Abstracts/Late-breaking opens
|
July 27, 2020
|
|
Deadline for 2nd Call for Abstract submissions
|
August 14, 2020
|
|
Deadline for presenting authors to register
|
August 28, 2020
|
| Online registration closes | September 30, 2020 |
Please indicate your preference for oral or poster presentation in the online submission. Due to the limited number of oral presentations available in the SHSA program, meritorious abstracts not assigned to oral presentation, will be accepted for posters. Abstracts submitted by commercial industry representatives may only be considered for poster presentation. Indicate in the online submission system if you do not wish to accept a poster presentation in this instance, in which case your abstract may be declined should it not be accepted for oral presentation. As the 5th SHSA Conference is now a virtual event, travel and educational grants will not be distributed.
An acknowledgement of your abstract submission(s) will be sent via email to the corresponding author.
Abstracts will be peer reviewed, following the submission deadline on Friday, July 3. Notifications will be sent to the accepted abstract submitters and accepted presenters by July 24th.
2nd Call for Abstracts: Abstracts will be peer reviewed, following the submission deadline on Friday, August 14. This submission deadline will not be extended. Notifications will be sent to the accepted abstract submitters and accepted presenters by the end of August.
Abstracts should present new information, and not have been submitted or published elsewhere (at the time of submission). When submitting an abstract, please select the topic that best applies to your abstract. Topics can be selected from the drop-down menu in the online submission system. Abstracts submitted by industry representatives may only be considered for poster presentation. Submitting authors and/or presenters may modify their submission(s) until the closing date.
Please submit your abstract by selecting one category out of the following that best describes its scientific content. Topics will be available in a drop-down menu on the online submission site. Categories will be used for reviewing and indexing purposes.
Authors are required to complete a Disclosure of Conflict form as part of the abstract submission. These will be included in the Final Program. Abstracts must be free of commercial bias and should only identify drug products by their generic names.
A condition of acceptance is that you must register for the conference no later than August 28, 2020 in order for the abstract to be included in the program.
Abstract Guidelines
Abstracts selected for presentations in the 5th Annual SHSA will be reproduced exactly as submitted and substitutions and changes will not be permitted after the closing date. Be sure to proofread your abstract very carefully before submitting.
Sponsors For sponsorship information of the 5th SHSA, please contact Annette McCunn at shsa@simplyeventful.com or call 604-738-8600.
The 5th SHSA 2020 gratefully acknowledges the support of the following Sponsors:
PLATINUM SPONSOR:
AbbVie
GOLD SPONSORS:
Appulse Medical
Incyte
Janssen
Pfizer
SILVER SPONSORS:
Chemocentryx
Novartis Pharmaceuticals Canada
UCB Biopharma
BRONZE SPONSOR:
Profound thanks to Dr. Ricardo Cibotti and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) for their support of the SHSA meeting and HS research.
Funding for this conference was made possible in part by R13AR077976 from NIAMS. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
To learn more about the 5th Annual SHSA or future SHSA meetings, please contact the Conference Secretariat for the Sponsorship Prospectus.
More info Final Program and Abstracts from previous conferences are available for download:
Join the conversation
